INTRODUCTION
MicroRNAs (miRNA) are a class of small non-coding RNAs that regulate gene expression through inhibition of translation or stability of target mRNAs. The biogenesis of miRNA involves multiple steps, including transcription of primary miRNA (pri-miRNA) by RNA polymerase II, cleavage of pri-mRNA to precursor miRNA (pre-miRNA) by Drosha, nucleocytoplasmic export of pre-miRNA by exportin-5 (XPO5), processing of pre-miRNA to mature miRNA by Dicer, and formation of functional RNA-induced Silencing Complex containing Argonaute (Krol et al., 2010) . Depending on the cellular context, a miRNA can function as an oncogene or a tumor suppressor (Croce, 2009 ). However, global downregulation of miRNA expression has been observed in many tumors (Lu et al., 2005) . Interestingly, systematic evaluation of miRNA levels in cancer cell lines demonstrated that many pre-miRNAs are retained in the nucleus (Lee et al., 2008) , implying that function of the nuclear-cytoplasmic export machinery may be compromised in tumors.
XPO5 is currently considered the indispensable transport receptor for pre-miRNA in most organisms examined (Katahira and Yoneda, 2011) . Upon binding to Ran-GTP, XPO5 uses a baseball mitt-like structure to shield the pre-miRNA stem region and the tunnel-like structure to recognize the 2-nucleotide 3′-overhang (Okada et al., 2009) . Following GTP hydrolysis, XPO5 releases the pre-miRNA into the cytoplasm. It has been proposed that XPO5 is unique among classical haploinsufficient tumor suppressor genes since partial, but not complete, loss promotes tumor development (Melo et al., 2010) . However, the exact role of XPO5 in tumor progression remains elusive. XPO5 is downregulated in lung cancer (Chiosea et al., 2007) , but upregulated in breast and prostate cancer (Leaderer et al., 2011) . Furthermore, the C/C genotype of rs11077 in the XPO5 3′UTR, which decreases XPO5 protein expression, is associated with poorer prognosis of esophageal and renal cancer (Horikawa et al., 2008) but better prognosis of non-small-cell lung cancer, multiple myeloma, and liver cancer (Liu et al., 2014) .
Development of hepatocellular carcinoma (HCC) is a multistep sequential process going from chronic inflammation, cirrhosis, primary HCC to metastatic HCC. It has been reported that aberrant miRNA expression drives HCC development and global miRNA downregulation at a later stage promotes metastasis (Wong et al., 2012) . Since the reduced miRNA expression in liver cancer is attributed to defective miRNA biogenesis (Lee et al., 2008) and the activity of XPO5 is the rate-limiting step for the production of mature miRNA (Yi et al., 2005) , we decided to investigate the role of XPO5 in liver cancer.
RESULTS

ERK Activation Suppresses Nuclear Export Activity of XPO5
To determine the role of XPO5 in the development of HCC, we first investigated the expression of XPO5 in liver cancer patients. Although the expression level of XPO5 was similar in normal and tumor tissues ( Figure S1A ), we noticed that more XPO5 was retained in the nucleus of tumor cells (Figures 1A and 1B) . Consistent with the findings from IHC staining, Western blot analysis showed nuclear localization of XPO5 in liver tumor lysates ( Figure 1C ). Because phosphorylation-dependent mobility shift could be detected by phostag (Kinoshita et al., 2006) in tumors, we further compared phosphorylation status of XPO5. Interestingly, serine phosphorylation of XPO5 was significantly increased in tumors ( Figure  1C ). XPO5 overexpression is known to increase nuclear export of pre-miRNA, leading to the enhanced inhibition of miRNA-targeted gene expression. Therefore, we assessed the effects of XPO5 phosphorylation on its function using an indicator luciferase reporter containing eight perfect miR-30a binding sites. Consistent with previous reports (Yi et al., 2005) , overexpression of XPO5 exports the endogenous miR-30 to inhibit luciferase expression ( Figure 1D ). Interestingly, when we co-transfected five different oncogenic serine/threonine kinases, including IKKα, IKKβ, myristoylated-AKT, MEKDD, or CDC2; only constitutively active MEK (MEKDD), which activates ERK, significantly reversed the effects of XPO5 ( Figure 1D ). In addition, ERK activation increased the slow-migrating and serine phosphorylated form of XPO5 ( Figure S1B ). The activities of these five kinases were confirmed using previously reported substrates ( Figure S1C ). Distribution of pre-miR-30 in the cytoplasm was reduced by knockdown of XPO5 and restored by overexpression of shRNA-resistant XPO5 (R-WT) ( Figure 1E ). In contrast, ERK activation by phorbol 12-myristate 13-acetate (PMA) or co-transfection with MEKDD abrogated the cytoplasmic accumulation of pre-miR-30 ( Figures 1E and S1D) . Treatment of cells with MEK1 inhibitor, PD98059, was found to reverse the decrease in pre-miR-30 triggered by PMA. Northern blot analysis confirmed inefficient pre-miRNA export in cells with activated ERK ( Figure S1E ).
Eukaryotic translation elongation factor 1A (eEF1A), a nuclear export substrate of XPO5 (Bohnsack et al., 2002) , was also used as a readout of XPO5 function. Consistently, MEK activation, whose effect can be reversed by dominant negative (DN) ERK, also blocks XPO5-mediated eEF1A nuclear export ( Figure 1F ). In summary, these results suggest that the activation of ERK inhibits nuclear export activity of XPO5.
ERK Phosphorylates XPO5 at T345, S416 and S497
To determine how ERK inhibits XPO5 activity, we first tested whether ERK interacts with XPO5. Co-immunoprecipitation experiments showed that XPO5 was associated with ERKs upon MEK activation ( Figure S2A ). Although ERK1 and ERK2 are highly similar and possess identical substrate specificity in vitro, we focused on the ERK2 because its expression exceeds that of ERK1 in most cells, and Erk2 knockout results in embryonic lethality while Erk1 knockout does not (Pages et al., 1999; Yao et al., 2003) . The interaction between endogenous ERK2 and XPO5 was observed after PMA stimulation ( Figure S2B ). After MEK stimulation, the phosphorylated ERK translocates into the nucleus to activate nuclear substrates or forms a dimer to activate cytoplasmic substrates (Casar et al., 2009) . As shown in Figure 2A , XPO5 does not interact with phosphorylation site mutant TAYF but still binds to dimerization mutant HEL 4 A of ERK, suggesting that XPO5 could be a nuclear substrate of ERK. Indeed, ERK co-localizes with XPO5 in the nucleus ( Figure 2B ).
ERK displays specificity for phosphorylation at the serine/threonine-proline (S/T-P) motif. Since the S/T-P motif is found in many proteins, ERK uses a docking motif to ensure its substrate specificity. The best characterized docking sites on ERK are the F-site recruitment site (FRS) and common docking (CD) domain, which responds to the F-site (FX-F/Y-P) and D domain (K/R 0-2 -X 1-6 -ϕ-X-ϕ) on substrates (Roskoski, 2012) . We found that CD mutant (321N), but not FRS mutant (263A) of ERK abolishes interaction with XPO5 ( Figure 2C ). Mutational analysis of three potential D domains of XPO5, identified by Eukaryotic Linear Motif database, further revealed that XPO5 residues 284-291 are critical for the association ( Figures 2C and S2C ).
Given the physical interaction between ERK and XPO5 and that calf intestinal alkaline phosphatase can eliminate the mobility shift of XPO5 induced by ERK ( Figure S2D ), we examined whether XPO5 is a physiological substrate of ERK. Phospho-S/T-P antibody detected XPO5 phosphorylation correlated with ERK activation (Figures S2E and S2F) . In vitro kinase assays and mutational analyses suggested that three highly conserved residues T345/S416/S497 of XPO5 are major ERK phosphorylation sites (Figures 2D, S2G and S2H) . Mass spectrometry analysis showed that ERK phosphorylated XPO5 at T345/S416 in vitro and S416 in vivo (Figures 2E and S2I) . Although phosphorylation at S497 was not detected by mass spectrometry, it was confirmed by a phosphorylation site specific polyclonal antibody ( Figure 2F ). The original intention was to generate all three phosphospecific antibodies, but only those against p-S416 and p-S497 were successful. Considering the nucleus-enriched specificity and stronger signal intensity ( Figure 2F ), p-S416 antibody was used as a tool to monitor XPO5 phosphorylation hereafter ( Figure S2J ). In conclusion, we demonstrate that ERK interacts with XPO5 and phosphorylates it at T345/S416/S497.
XPO5 Phosphorylation Globally Downregulates miRNA Expression
Before investigating how phosphorylation inhibits XPO5 activity, we first examined the functional importance of XPO5 phosphorylation in miRNA regulation. Comparison of the phosphorylation of ERK and XPO5 in a panel of liver cancer cell lines showed that XPO5 phosphorylation correlated positively with ERK phosphorylation ( Figure 3A ) and negatively with sensitivity to sorafenib ( Figure S3A ), a RAF inhibitor approved for the treatment of advanced liver cancer (Bai et al., 2009) . To show the global trend of miRNA expression, dot density plot was used to compare expression of 798 miRNAs identified by Nanostring nCounter miRNA expression assay. We found that XPO5-knockdown induced global downregulation of miRNA in the low ERK phosphorylated cell lines, Huh-7 and HepG2, which could be rescued by wild-type XPO5, but not a phosphomimetic 3D mutant ( Figures  3B and S3B) . Moreover, non-phosphorylatable 3A mutant upregulated miRNA expression more than wild-type XPO5 in the high ERK phosphorylated cell lines, SNU-423 and SKHep-1 (Figures S3C and S3D ). Based on relative expression levels, we classified the miRNA into three sets: downregulated (<0.67-fold), unchanged (0.67-to 1.5-fold), and upregulated (>1.5-fold) ( Figure S3E ). The 40 most abundantly expressed miRNAs were also selected to generate the heat map showing the trend of miRNA expression . The Huh-7 cell line was chosen as a model to study the effect of XPO5 phosphorylation hereafter because it exhibits the lowest ERK and XPO5 phosphorylation levels ( Figure 3A) . ERK activation by PMA, TGF-α, or MEKDD induced global downregulation of miRNA in the presence of wild-type XPO5, but this effect of ERK activation was attenuated in cells expressing 3A XPO5 ( Figure 3D ). These results support the notion that ERK activation leads to globally downregulated miRNA levels by phosphorylating XPO5 at T345/S416/ S497.
Considering that abundance of miRNA is crucial for miRNA function, expression levels of the top ten abundantly expressed miRNAs were validated by qRT-PCR ( Figure 3E ). MiR-122 is known to dominate the miRNA content in the normal adult liver (Jopling, 2012) . In Huh-7 cells, we noticed that miR-4454 and miR-720 are expressed at higher levels than miR-122, but are minimally affected by XPO5. MiRNA precursors fold into stem-loop structures and are recognized by XPO5; however, a large number of similar hairpins that are not pre-miRNAs can also be found in the genome and are called pseudo-hairpins. RNA-fold (Hofacker, 2003) shows these two pre-miRNAs have significantly higher minimum freeenergy ( Figure 3F ), and MiPred (Jiang et al., 2007) does not classify them as pre-miRNA like hairpins ( Figure S3I ). Consistent with the in silico prediction, RNA-binding protein immunoprecipitation (RIP) and RNA pull-down suggest miR-4454 and miR-720 minimally interact with XPO5, compared to miR-122 ( Figures 3G and S3J ).
Considering that Huh-7 cells resemble normal hepatocytes in expressing high levels of miR-122 (Chang et al., 2004) , miR-122 was chosen hereafter as a functional indicator for XPO5 phosphorylation-induced miRNA downregulation. Defective in pre-miR-122 export in 3D mutant expressing Huh-7 cells ( Figures 3H and S3K ) resulted in the de-repression of miR-122 targets as measured by miR-122 reporter luciferase or EGFP harboring miR-122 binding sites in the respective 3′-UTR ( Figures 3I and S3L ), indicating that miR-122 function is inhibited upon XPO5 phosphorylation.
Suppression of miR-122 Confers Taxol Resistance by Upregulating Septin-9
Because XPO5 phosphorylation decreased miR-122 expression and loss of miR-122 reduced chemosensitivity (Xu et al., 2011; Yang et al., 2011; Yin et al., 2011) , we examined whether phosphorylation of XPO5 confers chemoresistance. As shown in Figure 4A , taxol resistance was induced by 3D XPO5 and reversed by miR-122 mimetic. Knockdown of miR-122 (simiR-122) also increased taxol resistance, both in vitro and in vivo ( Figures 4A and S4A ). We then investigated whether inhibition of the ERK pathway could increase miR-122 and attenuate taxol resistance. As expected, sorafenib, an inhibitor to reduce ERK activation, increased miR-122 expression and sensitized tumor cells to taxol . However, the 3D XPO5 mutant was resistant to sorafenib-induced miR-122 accumulation and taxol sensitization, as confirmed by the upward shift of the combination index (CI) plot ( Figure 4D ). The importance of XPO5 phosphorylation in the synergism of ERK inhibition and taxol was further substantiated by DN-ERK and other pharmacological inhibitors of the RAF/MEK/ERK pathway ( Figure S4F ). miR-122 plays a central role in diverse hepatic functions, as highlighted by its direct role in fat metabolism, tumor suppression, inflammation and fibrosis . To find a therapeutic target to circumvent loss-of-miR-122-induced taxol resistance, we noticed that 5 of 30 genes identified by Gene ontology and biological association analysis of the miR-122 targets (Boutz et al., 2011) are associated with microtubule dynamics, including septin-2 (SEPT2), septin-9 (SEPT9), MAP1B, MAP4, and vimentin. Western blot analysis showed that SEPT9 was significantly increased in cells depleted of miR-122 ( Figure 4E ) and luciferase reporter assay indicated that miR-122 negatively regulates SEPT9 expression by interacting with its 3′ UTR ( Figure S4G ). Because septins may increase microtubule dynamics through scaffolding microtubule-associated proteins (MAP) and microtubule affinity regulating kinase (MARK) (Spiliotis, 2010) , we compared MAP4 phosphorylation in XPO5 stable transfectants and examined the role of MARK. MAP4 phosphorylation was higher in 3D XPO5 cells, resulting in susceptibility to MARK inhibitor (MARKI) (Figures 4F, 4G and S4H) . Consistently, miR-122 KO hepatocytes that express more SEPT9 are resistant to sorafenib, but sensitive to the combination of MARKI and taxol (Figures 4H and S4I) . We further knocked down four isoforms of MARK in 3D XPO5 cells and found MARK4 depletion significantly inhibited MAP4 phosphorylation to restore its association with tubulin, thereby conferring taxol sensitivity ( Figure 4I ). Combined with the finding that MARK4 is localized to microtubules (Trinczek et al., 2004) and upregulated in liver cancer ( Figure S4J ) (Kato et al., 2001) , our results suggest that MARK4 could be a therapeutic target to overcome taxol resistance caused by depletion of miR-122.
Pin1-Induced Conformational Changes in XPO5 Decrease Pre-miRNA Loading
To gain insight on how phosphorylation impairs XPO5 activity, we analyzed the structure of XPO5. Based on WESA (weighted ensemble solvent accessibility) algorithm (Chen and Zhou, 2005) and the secondary structure of XPO5 ( Figures S5A and S5B ), three ERK phosphorylation sites are fairly accessible and not part of defined helix structures. The structure of XPO5 resembles a flexible wound spring; therefore, small changes in the relative orientation of successive HEAT repeats could cumulatively generate substantial changes in the helicoidal pitch (Okada et al., 2009) . It has been shown that prolyl isomerase Pin1 interacts with proteins phosphorylated at S/T-P motifs, thereby controlling their activity by promoting cis-trans isomerization (Liou et al., 2011) . Because ERK phosphorylates substrate at S/T-P motifs, we investigated whether Pin1 plays a role in ERK-mediated impairment of XPO5 functions. Treatment of cells with two structurally distinct Pin1 inhibitors, juglone or PiB, was found to reverse the decrease in miR-122 triggered by PMA ( Figure 5A ). GST pull-down assay shows that ERK activation by ERK2-L4A-MEK1 fusion, a constitutively active and nuclear form of the ERK2, enhances wild-type, but not 3A, XPO5 to associate with Pin-1 ( Figure 5B) . The interaction between endogenous XPO5 and Pin-1 also increased when ERK was activated ( Figure S5C ). To investigate if Pin1 changes the conformation of XPO5, we performed partial proteolysis assay with subtilisin, a protease particularly sensitive to substrate conformation (Lu and Zhou, 2007) . Incubation with wildtype, but not with catalytically inactive K63A (Zhou et al., 2000) Pin1 mutant protects XPO5 from proteolytic cleavage ( Figure S5D ). Notably, Pin1 fails to protect 3A XPO5 from proteolysis. Given that Pin1 induces conformational changes in XPO5, we used PP2A, a trans-pSer/Thr-Pro isomer specific phosphatase (Zhou et al., 2000) , to examine the cis/trans status of XPO5. Wild-type, but not K63A, Pin1 prevents dephosphorylation of XPO5 by PP2A, indicating that trans-conformation of pSer/Thr-Pro motif on XPO5 was isomerized to cis-conformation in the presence of Pin1 ( Figure 5C ).
EMBOSS analysis (Jones et al., 2002) with WATER algorithm revealed that 416S at HEAT9 and 497S at HEAT10 of XPO5 aligned better with WFYS*PR, an optimal binding sequence for Pin1 (Yaffe et al., 1997) (Figure S5E ). Considering the inner helix of HEAT9 provides the closest contact with the stem of pre-miRNA (Okada et al., 2009) , we asked whether Pin1-induced conformational changes interfere pre-miRNA binding. Despite the availability of the crystal structure of XPO5, the disorder region in the helix of HEAT10 hampered accurate in silico simulation ( Figure S5B ). The structure, however, indicates that the possible rearrangement of helices 9 and 10 upon trans-to-cis conversion of P417 and P498, will obstruct pre-miRNA loading ( Figure 5D ). We therefore investigated whether the Pin1-induced XPO5 conformational changes contribute to ERK-mediated global miRNA downregulation. As shown in Figure 5E , miRNA expression was globally downregulated in cells expressing wild-type Pin1, but this effect was attenuated in the presence of K63A Pin1 or Pin1-binding-defective 3A XPO5. The assembly of the pre-miRNA/XPO5/Ran-GTP complex after Pin1-mediated isomerization was further examined. Because changes in accessibility to the MPM2 antibody have been suggested to reflect conformational changes induced by Pin1 (Stukenberg and Kirschner, 2001 ), we used it as a tool to evaluate the conformation of XPO5. Consistent with the in silico predictions, the conformation-altered XPO5 was not able to load pre-miR-122 ( Figures 5F and S5F) , resulting in the inhibition of pre-miR-122 export ( Figure S5G ), de-repression of miR-122 targets, and resistance to taxolinduced tubulin polymerization (Figures S5H-J) . The involvement of Pin1-mediated conformational changes in pre-miRNA loading can also be observed in HepG2 and SKHep-1 cells ( Figure S5K ). Considering that pancreatic cancer exhibits the highest incidence of KRAS mutations and that melanoma has the highest rate of BRAF mutations (Cheng et al., 2013; Neuzillet et al., 2013) , we investigated whether ERK-mediated impairment of XPO5 functions also occurs in these two types of cancer. Our results demonstrated that Pin1-induced XPO5 conformational changes contribute to KRAS G12V and BRAF V600E -induced impairment of XPO5 function in pancreatic cancer and melanoma, respectively ( Figure S5L and S5M).
Because phosphorylated XPO5 is enriched in the nucleus ( Figure 2F ), we also examined the role of Pin1 in XPO5 localization. As shown in Figure 5G , Pin1 loss-of-function partially restored nuclear export of XPO5 and interaction with NUP153, which is essential in the nuclear export of the pre-miRNA-XPO5 complex (Wan et al., 2013) . Interestingly, it has been reported that ERK is a physiological nucleoporin kinase that targets the FG repeat regions to disrupt karopherin-nucleoporin interactions. ERK phosphorylates nucleoporin NUP153 at Ser257, Ser320, Ser334, Ser338, Thr369, Thr388, Thr413, Ser516, Ser522 and Ser529. Through generating phospho-specific antibodies, it was shown that ERK directly phosphorylates NUP153 at least at Ser338 and Ser529 (Kosako et al., 2009 ). NUP153 was not found to directly bind Pin1 ( Figure S5N ). We found non-phosphorylatable S 257 A/ S 320 A/S 334 A/S 338 A/T 369 A/T 388 A/T 413 A/S 516 A/S 522 A/S 529 A (10A) NUP153 further restored the interaction with XPO5 in cells expressing catalytically inactive Pin1 with activated ERK, resulting in the export of XPO5 and pre-miR-122 (Figures 5G, 5H and S5O). These results support the conclusion that ERK phosphorylates both XPO5 and NUP153 to trap XPO5 and pre-miRNA in the nucleus.
XPO5 Phosphorylation Promotes Tumor Development and Associates with Poor Prognosis
We showed above that depleting Pin1 or MARK4 may increase taxol sensitivity in XPO5-phosphorylated cells (Figures 4I and S5J) . Indeed, inhibition of Pin1 or MARK4 restored taxol-induced tubulin polymerization ( Figure S6A ), reduced cell viability ( Figure 6A ), and decreased tumor burden ( Figures 6B and S6B ). These data support the idea that Pin1 and MARK4 could be therapeutic targets in XPO5 phosphorylation-associated drug resistance. Although the XPO5 phosphomimetic did not significantly increase Huh-7 cell proliferation in vitro ( Figure S6C ) in 2 days, we noticed that in vivo tumor growth was increased when 3D XPO5 was expressed ( Figures 6C and S6D) . Interestingly, the cancer stem cell marker CD133 and EPCAM is detected in the liver of young miR-122 KO mice, followed by further increase in the tumors Tsai et al., 2012) . Consistently, we found cell surface markers CD133 and EPCAM, functional marker aldehyde dehydrogenase (ALDH) activity, and tumor sphere formation was increased in 3D XPO5 cells, but attenuated when miR-122 was overexpressed or Pin1 was knocked down (Figures 6D, 6E, S6E and S6F) . Taken together, our data supports the conclusion that XPO5-dependent downregulation of miRNA contributes to tumor development through increasing cancer stem cell formation and chemoresistance.
To examine whether these conclusions are in accord with findings in human tumors, we performed nanostring miRNA profiling and immunoblotting using 12 paired HCC tumor specimens and adjacent normal tissues. XPO5 phosphorylation was found to be associated with global miRNA downregulation ( Figures 6F, 6G and S6G ). Because miR-122 dominates the miRNA content in the normal liver, we choose it as an indicator and studied its expression using liver tumor tissue array that contained 59 HCC specimens. Consistent with our findings, XPO5 phosphorylation was associated with ERK phosphorylation, miR-122 downregulation, and SEPT9 expression ( Figures 6H and S6H) . We next correlated our findings with patient survival. The Kaplan-Meier survival curves showed that high p-XPO5 (S416) were associated with poor survival ( Figure 6I ). Moreover, p-XPO5/p-ERK double positive patients had reduced overall survival relative to the p-XPO5 negative/p-ERK positive group (Figure S6I ), supporting that ERK-mediated phosphorylation of XPO5 is associated with worse prognosis. Consistent with the discovery cohort, we also observed that XPO5 phosphorylation correlated with poor survival in the validation cohort ( Figure S6J) . A sex, age, stage, and adjacent liver status (normal, viral hepatitis, viral hepatitis related cirrhosis)-adjusted multivariate regression analysis suggested that p-XPO5 was independently associated with patient survival ( Figure S6K ). Taken together, analyses of tumor specimens further strengthened the notion that phosphorylation of XPO5 by ERK downregulates miRNA expression and is associated with poor clinical outcome of liver cancer patients.
DISCUSSION
Hepatocellular carcinoma is often diagnosed at advanced stages when surgery is not feasible and is also highly resistant to conventional chemotherapy. Therefore, identification of signaling pathways regulating liver carcinogenesis is important in developing targeted therapy. In this study, we demonstrated that ERK phosphorylates XPO5 to impair its ability to export pre-miRNA. However, ERK is also known to increase Drosha and Dicer by phosphorylating DGCR8 and TRBP, a consequence of increasing pro-growth miRNA levels (Herbert et al., 2013; Paroo et al., 2009 ). Further investigation is therefore needed to establish how ERK affects miRNA biogenesis. It is important to mention that nuclear export by XPO5 has been suggested as a rate-limiting step in miRNA biogenesis. Only XPO5, but not Drosha or Dicer, overexpression enhances inhibition of gene expression by miRNA (Yi et al., 2005) . Concordant with our results, most miRNAs were downregulated in PMAtreated myeloid leukemia (Wang et al., 2013) and upregulated in sorafenib-treated HCC . But in colon cancer, which has been reported to express an XPO5 frameshift mutant (Melo et al., 2010) , expression of miRNAs was upregulated by KRAS and inhibited by MEK/ERK inhibitors (Ragusa et al., 2012) . Based on our results and the published literature, an interesting model can be proposed: in cells with wild-type XPO5, activated ERK phosphorylates XPO5, which results in decreased miRNA production. However, if XPO5 is mutated, the effect of ERK on Drosha and Dicer becomes apparent, meaning ERK can globally increase miRNA expression. This model suggests that XPO5 plays a critical role in deciding how ERK reprograms miRNA biogenesis.
Shuttling of RNAs and proteins out of the nucleus is essential in maintaining normal cellular function. Cancer cells can usurp this process to stimulate tumor growth and evade apoptosis (Gravina et al., 2014) . However, among all of the potential targets in nucleo-cytoplasmic transport, only XPO1 is better understood and is inhibited by selective inhibitor of nuclear export (SINE), which is currently in phase 2 clinical trial (Gerecitano, 2014 ). An in-depth understanding of miRNA export machinery is needed for the successful design of clinical therapeutics. Our study showed that ERK phosphorylation followed by Pin1-mediated isomerization impairs XPO5 activity. These findings suggest that XPO5 and global miRNA downregulation may become druggable targets, although systems biology and network analysis are necessary to determine the effect of XPO5 restoration in a holistic manner. Pin1 is an attractive target for designing small molecule inhibitors because of its well-defined active site. However, the available Pin1 inhibitors still lack the required specificity and potency (Moore and Potter, 2013) . Interestingly, a recent report showed that all-trans retinoic acid (ATRA) directly binds and degrades the active form of Pin1 that is overexpressed in cancer (Wei et al., 2015) . Thus, development of more potent and specific Pin1-targeted ATRA derivatives may be a strategy to restore XPO5 function.
XPO5 is the only known transporter to export pre-miRNA to the cytoplasm. In our study, we found that cells with XPO5 knockdown or phosphomimetic XPO5 were characterized as having global down-regulation of miRNA expression. Nonetheless, nanostring nCounter analysis revealed that some miRNAs levels were not altered by the impairment of the XPO5. Two splicing-independent mirtrons, miR-1225 and 1228, are also known to be independent of XPO5 for their biogenesis (Havens et al., 2012) . We plan to use affected and unaffected pre-miRNA, such as pre-miR-122 and pre-miR-221, as probes to seek additional nuclear export pathways. Among the miRNAs downregulated after XPO5 phosphorylation, we further explored the consequence of miR-122 reduction because it is an abundant liverspecific miRNA and is essential for the maintenance of liver homeostasis. Previous reports suggested that restoring miR-122 may be a strategy to limit HBV/leishmania infection, suppress HCV negative HCC, and prevent the development of nonalcoholic steatohepatitis and cirrhosis (Thakral and Ghoshal, 2015) . However, the efficacy of the miRNA mimetic and delivery method still needs to be resolved before advancing to clinical trial. An alternative method to restore miRNA function is to attack downstream targets of the miRNA. Our results suggest that MARK4 may be a therapeutic target to overcome miR-122 lossinduced tumorigenesis and drug resistance. Although the crystal structure of MARK4 is still unknown, combined molecular dynamic simulation and pharmacophore-based virtual screening recently identified six potent compounds specific for MARK4 (Jenardhanan et al., 2014) . These lead compounds deserve further testing as potential candidates for miR-122-related diseases.
In summary, we propose a model based on the current findings for ERK-induced tumorigenesis in liver cancer cells (Figure 7 ). In the absence of ERK activation, premiR-122 is exported by XPO5 from nucleus to cytoplasm through the nuclear pore complex to produce mature miR-122 to inhibit SEPT9 expression. Un-phosphorylated MAP4 binds to tubulin, causing cells to respond to taxol (left panel). When ERK is activated, XPO5 is phosphorylated at T345/S416/S497, followed by isomerization by Pin1, which impairs its ability to load pre-miR-122. ERK also phosphorylates NUP153 to further inhibit premiRNA-XPO5 complex export. SEPT9 then acts as a scaffold for MAP4 and MARK4 and causes phosphorylated MAP4 to detach from microtubules to impart taxol resistance (right panel). The identification of XPO5 as a downstream substrate for ERK links the mitogenic signaling and miRNA nuclear export machinery, and suggests that strategies toward restoring the activity of XPO5 may have therapeutic value.
EXPERIMENTAL PROCEDURES Mouse model for tumorigenesis
All mice were handled according to the procedures approved by Ohio State University Institutional Laboratory Animal Care and Use Committee.
Human liver tumor samples
The Ohio State University Institutional Review Board approved this study. Primary human liver cancer and adjacent normal tissues were obtained from the Cooperative Human Tissue Network at the Ohio State University James Cancer Hospital. Informed consent was obtained from all patients.
Statistical analysis
Each experiment was performed at least three times, and representative data are shown. Data in bar graph are given as the mean ± SEM. Means were checked for statistical difference using Student's t test or Pearson's chi-square test, and p values less than 0.05 were considered significant (* p<0.05, ** p<0.01, *** p<0.001). For dot density plot, MannWhitney rank sum test was applied. For survival analysis, Kalpan-Meier analysis and logrank test were applied.
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Refer to Web version on PubMed Central for supplementary material.
Significance
Systemic analysis of miRNAs has revealed that many pre-miRNA are retained in the nucleus of cancer cells. In this study, we have identified that ERK phosphorylation coupled with Pin1-mediated conformational changes in XPO5 inhibits miRNA export. Global downregulation of miRNA expression including that of miR-122 is observed in liver cancer when XPO5 is phosphorylated. Depletion of miR-122 activates MARK4 to increase microtubule dynamics, thereby inducing drug resistance and tumorigenesis. Furthermore, XPO5 phosphorylation correlates with poor prognosis in liver cancer patients. Our findings identified a mechanism of global downregulation of miRNA in liver cancer and targets, Pin1 and MARK4, for therapeutic intervention. (Zeng et al., 2002) . Cytoplasmic RNA was extracted using PARIS kit then detected by qRT-PCR. Data were presented as relative to the cytoplasmic pre-miR-30 expression in siCTL 293T cells transfected with pCMV-miR-30 (n=3 per group, data represents mean ± SEM, p values were calculated by Student's t test). (F) siCTL cells were transfected with MEKDD with or without DN-ERK, while siXPO5 cells were transfected with siRNA-resistant XPO5 (R-WT) with or without MEKDD. All cells were co-transfected with GFP-NLS-eEF1A and observed by florescence microscopy after 48 hr. Scale bars: 50 μm. See also Figure S1 . Characterization of p-XPO5 (S416) and p-XPO5 (S497) antibodies by IB analysis of cytosolic, nuclear, and total lysates of 293T cells transfected as indicated with MEKDD, ERK2, and WT or non-phosphorylatable alanine mutant (3A) XPO5. See also Figure S2 . WT or non-phosphorylatable 3A XPO5 expressing Huh-7 cells were treated with 100 nM PMA, 100 ng/ml TGF-α or transfected with MEKDD for 48 hr. Data were presented as relative to the miRNA expression in untreated R-WT Huh-7 cells (n=2). Inset: IB of ERK phosphorylation across treatment groups. WT or non-phosphorylatable 3A XPO5 expressing Huh-7 cells were treated with 100 nM PMA, 100 ng/ml TGF-α for 30 min or transfected with MEKDD for 48 hr. (E) Top ten highly expressed miRNAs in Huh-7 stable transfectants were quantified by qRT-PCR. miRNA expression was normalized to RNU48 (n=3 per group, (A) Huh-7 cells were pre-treated with or without 5 μM juglone or 5 μM PiB for 1 hr then treated with 100nM PMA for 24 hr before measuring miR-122 by qRT-PCR. Data were presented as relative to the miR-122 expression in the Huh-7 cells without drug treatment (n=3 per group, data represents mean ± SEM, p values were calculated by Student's t test). (B) Lysates of 293T cells transfected as indicated were incubated with GST-Pin1 then subjected to GST pull-down and IB. (C) Ectopically expressed myc-XPO5 was purified from Pin1 knocked down 293T cells followed by phosphorylation with active ERK2. Purified XPO5 was then incubated with GST, GST-Pin1, or GST-Pin1 (K63A) for 30 min before PP2A treatment for 5 min. (D) Relative position of P417 and P498 (red) in the crystal structure of XPO5 (gray, PDB 3A6P) in complex with RanGTP (cyan) and pre-miR30a (green and pink). Possible movements of helices 9 and 10 when changed to cis form are shown as red arrows. (E) miRNA of Huh-7 Flag-ERK2-MEK1 stable transfectant with Pin1-depleted (siPin1), siRNA-resistant Pin1 (R-WT), catalytic inactive K63A Pin1, or Pin1-binding-defective 3A XPO5 were profiled by nanostring assay. Data were presented as Under basal condition, pre-miR-122 is exported by XPO5 to produce mature miR-122 to inhibit SEPT9 expression. Un-phosphorylated MAP4 binds to tubulin to maintain taxol sensitivity. When ERK is activated, XPO5 is phosphorylated followed by isomerization by Pin1, which impairs its ability to load pre-miR-122. SEPT9 then acts as a scaffold for MAP4 and MARK4 to cause phosphorylated MAP4 to detach from microtubules therefore conferring taxol resistance.
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